Rebuilding trust in proton pump inhibitor therapy

Introduction of proton pump inhibitor (PPI) therapy into clinical practice has revolutionized treatment approach to acid-related diseases. With its clinical success came a widespread use of PPI therapy. Subsequently, several studies found that PPIs were oftentimes overprescribed in primary care and emergency setting, likely attributed to seemingly low side-effect profile and physicians having low threshold to initiate therapy. However, now there is a growing concern over PPI side-effect profile among both patients and providers. We would like to bring more awareness to the currently available guidelines on PPI use, discuss clinical indications for PPIs and the evidence behind the reported side-effects. We hope that increased awareness of proper PPI use will make the initiation or continuation of therapy a well informed and an evidence-based decision between patient and physician. We also hope that discussing evidence behind the reported side-effect profile will help clarify the growing concerns over PPI therapy.

[1]  S. Spechler,et al.  ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. , 2021, The American journal of gastroenterology.

[2]  Die Fan,et al.  No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort of 0.44 Million Participants , 2021, The American journal of gastroenterology.

[3]  A. Barkun,et al.  Proton pump inhibitors and risk of gastric cancer: population-based cohort study , 2021, Gut.

[4]  A. Barkun,et al.  ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding , 2021, The American journal of gastroenterology.

[5]  P. Paśko,et al.  Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy—A Literature Review , 2021, International journal of environmental research and public health.

[6]  Z. McMahan,et al.  A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis. , 2021, Best practice & research. Clinical rheumatology.

[7]  M. Melbye,et al.  Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  R. Valera,et al.  Adverse Effects Associated with Proton Pump Inhibitor Use , 2021, Cureus.

[9]  J. Schold,et al.  Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression , 2020, BMC Nephrology.

[10]  J. Pandolfino,et al.  AMBULATORY REFLUX MONITORING GUIDES PROTON PUMP INHIBITOR DISCONTINUATION IN PATIENTS WITH GASTROESOPHAGEAL REFLUX SYMPTOMS: A CLINICAL TRIAL. , 2020, Gastroenterology.

[11]  E. Savarino,et al.  EFFICACY OF THERAPY FOR EOSINOPHILIC ESOPHAGITIS IN REAL-WORLD PRACTICE. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  M. Walker,et al.  Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics , 2019, Gastroenterology research.

[13]  J. Cooke,et al.  Cardiovascular Risk of Proton Pump Inhibitors. , 2019, Methodist DeBakey cardiovascular journal.

[14]  W. Leung,et al.  Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence , 2019, Therapeutic advances in gastroenterology.

[15]  Avinash B. Kumar,et al.  The risks of long-term use of proton pump inhibitors: a critical review , 2018, Therapeutic advances in drug safety.

[16]  A. Hoes,et al.  Use of proton pump inhibitors and risk of iron deficiency: a population‐based case–control study , 2018, Journal of internal medicine.

[17]  Prashanth Rawla,et al.  Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? , 2018, World journal of gastrointestinal pharmacology and therapeutics.

[18]  Kelley E. Capocelli,et al.  Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. , 2018, Gastroenterology.

[19]  D. Graham Optimal PPI Dosing for Improving GERD Symptoms: Is Timing Everything? , 2018, Digestive Diseases and Sciences.

[20]  Yousef Nassar,et al.  Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis , 2018, Journal of bone metabolism.

[21]  J. Keller What Is the Impact of High-Resolution Manometry in the Functional Diagnostic Workup of Gastroesophageal Reflux Disease , 2018, Visceral Medicine.

[22]  C. Calderón-Ospina,et al.  Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences , 2018, Neural plasticity.

[23]  W. Lewis,et al.  Outcomes after laparoscopic anti-reflux surgery related to obesity: A systematic review and meta-analysis. , 2018, International journal of surgery.

[24]  K. Thavorn,et al.  The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  A. Ciobica,et al.  Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis , 2017, World journal of gastroenterology.

[26]  P. Moayyedi,et al.  ACG and CAG Clinical Guideline: Management of Dyspepsia. , 2017, The American journal of gastroenterology.

[27]  F. Bazzoli,et al.  Proton pump inhibitors: Risks of long‐term use , 2017, Journal of gastroenterology and hepatology.

[28]  K. Koh,et al.  Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis , 2017, Journal of gastroenterology and hepatology.

[29]  S. Paterson-Brown,et al.  Long‐term outcomes following laparoscopic anterior and Nissen fundoplication , 2017, ANZ journal of surgery.

[30]  D. Freedberg,et al.  The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. , 2017, Gastroenterology.

[31]  W. Chey,et al.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection , 2017, The American Journal of Gastroenterology.

[32]  A. Bredenoord,et al.  Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults , 2017, United European gastroenterology journal.

[33]  E. Savarino,et al.  The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. , 2017, European journal of internal medicine.

[34]  Shujie Chen,et al.  Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth , 2017, Journal of Gastroenterology.

[35]  A. Hoes,et al.  Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  A. Zullo,et al.  Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression , 2016, BMC Medicine.

[37]  Jeffrey H William,et al.  Magnesium Deficiency and Proton‐Pump Inhibitor Use: A Clinical Review , 2016, Journal of clinical pharmacology.

[38]  L. Laine,et al.  Long-Term PPI Use: Balancing Potential Harms and Documented Benefits , 2016, The American Journal of Gastroenterology.

[39]  Wenjie Xiong,et al.  Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[40]  Josef Coresh,et al.  Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. , 2016, JAMA internal medicine.

[41]  Nicholas J Shaheen,et al.  ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus , 2016, The American Journal of Gastroenterology.

[42]  J. Lam,et al.  Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis , 2015, PloS one.

[43]  Y. Huang,et al.  Proton-pump inhibitors and risk of fractures: an update meta-analysis , 2015, Osteoporosis International.

[44]  Eun Hye Kim,et al.  The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis , 2014, PloS one.

[45]  M. Klemp,et al.  Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis , 2014, BMJ Open.

[46]  R. Fanelli,et al.  Guidelines for the management of hiatal hernia , 2013, Surgical Endoscopy.

[47]  E. Dellon,et al.  Clinical Guideline : Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis ( EoE ) , 2013 .

[48]  Sang Min Park,et al.  Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. , 2013, World journal of gastroenterology.

[49]  J. Tajti,et al.  The effects of laparoscopic Nissen fundoplication on Barrett's esophagus: Long-term results , 2012, Scandinavian Journal of Gastroenterology.

[50]  T. G. Ellington,et al.  Proton Pump Inhibitor Therapy Use Does Not Predispose to Small Intestinal Bacterial Overgrowth , 2011, The American Journal of Gastroenterology.

[51]  J. Horn,et al.  Clinical Pharmacology of Proton Pump Inhibitors , 2012, Drugs.

[52]  Prateek Sharma,et al.  American Gastroenterological Association medical position statement on the management of Barrett's esophagus. , 2011, Gastroenterology.

[53]  R. Jensen,et al.  Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium , 2010, Current gastroenterology reports.

[54]  H. Echizen,et al.  Drug-Drug Interaction Profiles of Proton Pump Inhibitors , 2010, Clinical pharmacokinetics.

[55]  N. Kassam,et al.  Safety of the long-term use of proton pump inhibitors. , 2010, World journal of gastroenterology.

[56]  E. Wittbrodt,et al.  Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis , 2009, Clinical and experimental gastroenterology.

[57]  F. Chan,et al.  Guidelines for Prevention of NSAID-Related Ulcer Complications , 2009, The American Journal of Gastroenterology.

[58]  N. Shaheen,et al.  American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. , 2008, Gastroenterology.

[59]  J. Gregor,et al.  Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[60]  B. Batuwitage,et al.  Inappropriate prescribing of proton pump inhibitors in primary care , 2007, Postgraduate Medical Journal.

[61]  Yu-Xiao Yang,et al.  Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.

[62]  C. Scarpignato,et al.  Review article: the opportunities and benefits of extended acid suppression , 2006, Alimentary pharmacology & therapeutics.

[63]  G. Sachs,et al.  Review article: the clinical pharmacology of proton pump inhibitors , 2006, Alimentary pharmacology & therapeutics.

[64]  H. Blume,et al.  Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors , 2006, Drug safety.

[65]  B. Cooper,et al.  Oesophageal pH monitoring in Barrett's oesophagus , 2003, Gut.

[66]  C. Stedman,et al.  Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.

[67]  T. Ishizaki,et al.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[68]  Stewart,et al.  Iron absorption in patients with Zollinger–Ellison syndrome treated with long‐term gastric acid antisecretory therapy , 1998, Alimentary pharmacology & therapeutics.